NAGE

Niagen Bioscience, Inc. Common Stock

7.78 USD
+0.16
2.10%
At close Apr 29, 4:00 PM EDT
After hours
7.87
+0.09
1.16%
1 day
2.10%
5 days
8.81%
1 month
12.75%
3 months
31.86%
6 months
114.92%
Year to date
41.97%
1 year
118.54%
5 years
57.49%
10 years
73.66%
 

About: Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Employees: 104

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

644% more call options, than puts

Call options by funds: $1.53M | Put options by funds: $206K

486% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 7

85% more capital invested

Capital invested by funds: $64.3M [Q3] → $119M (+$54.5M) [Q4]

46% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 24

34% more funds holding

Funds holding: 91 [Q3] → 122 (+31) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$11
41%
upside
Avg. target
$11
41%
upside
High target
$11
41%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
37% 1-year accuracy
121 / 329 met price target
41%upside
$11
Buy
Reiterated
8 Apr 2025

Financial journalist opinion

Based on 4 articles about NAGE published over the past 30 days

Neutral
Business Wire
17 hours ago
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB). Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of.
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board
Neutral
Business Wire
1 day ago
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025, which ended March 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours o.
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
Neutral
Business Wire
3 weeks ago
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, reaffirms that the manufacturing of its Niagen® ingredient (patented nicotinamide riboside or NR) and Tru Niagen® and pharmaceutical-grade Niagen® products remain resilient amid the recently enacted global tariffs. Manufactured in the U.S. by the Company's partner, W.R. Grace, Niagen is rig.
Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs
Neutral
Business Wire
3 weeks ago
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, reaffirms that the manufacturing of its Niagen® ingredient (patented nicotinamide riboside or NR) and Tru Niagen® and pharmaceutical-grade Niagen® products remain resilient amid the recently enacted global tariffs. Manufactured in the U.S. by the Company's partner, W.R. Grace, Niagen is rig.
Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments
Neutral
Business Wire
1 month ago
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #IP--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent 12,252,506, which covers the composition of matter for nicotinamide riboside (NR) salt forms, including NR Malate and NR Tartrate, and other NR derivatives. This is p.
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
Neutral
Business Wire
1 month ago
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (Nasdaq: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today confirmed it has changed its corporate name to Niagen Bioscience, Inc. (“Niagen Bioscience” or the “Company”) and the Company's common stock will begin trading under the new Nasdaq symbol “NAGE” at stock market open today, Wednesday, March 19, 2025. The CUSIP number for the Company's.
ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science
Charts implemented using Lightweight Charts™